Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, United Kingdom.
Dis Colon Rectum. 2013 Dec;56(12):1366-72. doi: 10.1097/DCR.0b013e3182a62b0d.
Pseudomyxoma peritonei is a diffuse peritoneal malignancy that generally originates form a perforated appendiceal tumor. Optimal treatment requires extensive surgical resection to achieve complete cytoreduction combined with hyperthermic intraperitoneal chemotherapy. In a proportion of patients this is impossible, in particular, owing to extensive irresectable small-bowel involvement. There is ongoing debate as to the role of maximal tumor debulking in such cases.
: The aim of this study was to assess the outcomes of patients who underwent major tumor debulking for pseudomyxoma peritonei of appendiceal origin and to compare outcomes with patients who had complete cytoreduction during the same period.
This is a retrospective study.
This investigation was conducted at a tertiary referral center for peritoneal surface malignancy.
A prospective database of 953 consecutive patients with peritoneal malignancy undergoing surgery at a UK national referral center between 1994 and 2012 was analyzed. Of these patients, 748 (78%) had surgery for pseudomyxoma peritonei of appendiceal origin.
Survival, morbidity, and mortality in both groups were compared. Univariate and multivariate analyses were performed to identify negative prognostic factors in the group that underwent major tumor debulking.
Complete cytoreductive surgery was achieved in 543/748 (73%) patients, and 205 (27%) had maximal tumor debulking. Median age was 56 years (172 (31.7%) men) in the complete cytoreductive surgery group and 59 years (108 (52.7%) men) in the maximal tumor debulking group. Overall survival at 3, 5, and 10 years was 90%, 82%, and 64% in the complete cytoreductive group and 47%, 30%, and 22% in the maximal tumor debulking group. The median survival in the maximal tumor debulking group was 32.8 months (95% CI, 24.1-41.5).
The retrospective analysis of prospective data was a limitation of this study.
Maximal tumor debulking may help patients with pseudomyxoma peritonei in whom complete cytoreduction cannot be achieved with almost half alive at 3 years with long-term survival in some.
假性黏液瘤是一种弥漫性腹膜恶性肿瘤,通常起源于穿孔的阑尾肿瘤。最佳治疗需要广泛的手术切除,以实现完全细胞减灭术,并结合腹腔内热化疗。在一定比例的患者中,这是不可能的,特别是由于广泛的不可切除的小肠受累。对于这种情况,最大限度地切除肿瘤的作用仍存在争议。
本研究旨在评估接受阑尾来源假性黏液瘤最大肿瘤减灭术的患者的结局,并将其与同期行完全细胞减灭术的患者的结局进行比较。
这是一项回顾性研究。
本研究在英国国家腹膜表面恶性肿瘤转诊中心进行。
对 1994 年至 2012 年间在英国国家转诊中心接受手术治疗的 953 例连续腹膜恶性肿瘤患者的前瞻性数据库进行了分析。在这些患者中,748 例(78%)患有阑尾来源的假性黏液瘤。
比较两组患者的生存、发病率和死亡率。对行最大肿瘤减灭术的患者进行单因素和多因素分析,以确定预后不良的因素。
在 748 例患者中,543 例(73%)患者达到完全细胞减灭术,205 例(27%)患者行最大肿瘤减灭术。完全细胞减灭术组的中位年龄为 56 岁(172 例男性,占 31.7%),最大肿瘤减灭术组的中位年龄为 59 岁(108 例男性,占 52.7%)。完全细胞减灭术组 3、5、10 年总生存率分别为 90%、82%和 64%,最大肿瘤减灭术组分别为 47%、30%和 22%。最大肿瘤减灭术组的中位生存期为 32.8 个月(95%CI,24.1-41.5)。
本研究为前瞻性数据的回顾性分析,存在一定局限性。
对于无法行完全细胞减灭术的假性黏液瘤患者,最大肿瘤减灭术可能有助于患者,其中近一半的患者在 3 年内存活,一些患者的长期生存率较高。